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Clinical Practice Guidelines for the Management of Ischemic Stroke in Pakistan
Background
Diagnostic Approach
Shafqat
Section of Neurology, Department of Medicine, Aga Khan University Medical College. Karachi.
S.
Ischemic stroke represents a huge global burden,
being the leading cause of physical disability and the third-
leading cause of death worldwide.r Although rigorous
epidemiological data from Pakistan are lacking, stroke is
certainly the commonest reason for admission to a neurology
ward in our part of the world, as elsewhere. Recent years have
seen a number of new developments in the clinical approach
to stroke, including in the areas of diagnostic work-up, acute
treatment and secondary prevention. These developments
enable the formulation of clinical practice guidelines for
achieving standardized management of ischemic stroke, with
the overall aini of improving the care of stroke patients. This
article presents a set of guidelines that may be useful to
clinicians involved in the care of stroke patients in Pakistan.
The term 'stroke' is used here to refer exclusively to ischemic
brain infarction; this paper does not address intracerebral
hemorrhage.
The diagnostic approach to suspected stroke is
summarized in the accompanying algorithm (Figure). Any
sudden-onset focal neurological deficit must be considered a
stroke unless proven otherwise. The first step in the
evaluation of suspected stroke is medical stabilization with
attention to airway, breathing and circulation. The second
step is imaging of the brain, either with CT scar, if seen within
3 hours of symptom-onset, or preferably MR1 if the patient is
seen later. Patients seen within 3 hours of stroke onset may be
eligible for treatment with the intravenous thrombolytic agent
r-t-PA (recombinant tissue plasminogen activator)'-, as noted
in the accompanying algorithm; in practice, this constitutes
only a very small percentage of stroke patients because most
patients arrive outside the tirne window. Any patient being
considered for thrombolytic treatment must undergo
i mmediate non-contrast cranial CT scan. If the scan is
normal, the thromboiysis checklist can be initiated.
All patients (whether they receive rt-PA or not)
undergo a set of diagnostic tests to determine stroke subtype,
which forms the basis for rational secondary prevention. This
i ncludes (i) cardiac evaluation (ECC and transthoracic
echocardiogram with air-contrast); and (ii) cranio-cervical
vascular evaluation (carotid duplex ultrasound for anterior
circulation ischemia and MRA for posterior circulation
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ischernia). Additional tests including Iloiter monitoring.
transesophageal echocardiography or blood hypercoaguiability
profile, may be considered in cases of embolic stroke
-
where the
initial work-up is negative. The goal of this work-up is to
assign patients to one of four categories: small-vessel stroke
(lacunar stroke); large-vessel stroke (atherothrornbosis in
large-caliber artery such as internal carotid or bas'lar);
embolic stroke (infarction in a major vascular territory such
as major branches off the Circle of Willis or in the vertebro-
basilar system); or unclear 3
Acute thrombolysis
Acute treatment of the stroke patient includes
intravenous rt-PA for patients seen within 3 hours of
symptom-onset, as noted above. Time of onset is determined
from when the patient was last seer] to be well; this is
especially important for patients who wake lip with their
deficit. The cost of the usual adult dose of rt-PA for stroke
approaches Rs.100,000 in Pakistan. Although of proven
efficacy is improving functional stroke outcome. the drug is
associated with a I0-fold increase in the risk of symptomatic
i ntracerebral hemorrhage.'- These factors underscore tile need
to use rt-PA in stroke after careful clinical judgment and with
detailed informed consent of patient and/or next of kin. The
use of rt-PA should not be considered for patients who cannot
be evaluated by a neurologist. Contraindications to the use of
rt-PA are summarized in Figure.
Other acute considerations
All patients (whether they receive rt-PA or not), need
careful evaluation and concurrent management of co-morbid
conditions as appropriate, including diabetes mellitLIs,
coronary artery disease, renal dysfunction and/or liver
disease. If needed, blood pressure should be gently brought
down under systolic i 85 and diastolic I I0.'-
Assessment sllouid be made with regards to
swallowing. For nnild strokes, this can be done by asking the
patient to swallow small sips of water while observing for
cough or change it, voice. If the patient fails to swallow
properly, o€~ i f stroke severity precludes swallou - i ng
assessment, a nasogastric tube must be maintained.
Most patients will also require urinary catheterization
with a Foley catheter. In males without a history of prostate
symptoms, a condom, catheter should be tried first.
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Consider alternative
diagnoses
Consider re-imaging later
MRi (preferred) or CT
(add MRA for posterior
circulation stroke)
Onset _> 3 hrs or
thrombolysis
contraindicated
Oxygen
BP to< 1851110
SQ heparin
Swallowing assessment
Urinary catheter
ECG
Echocardiogram (with
air contrast)
Carotid dopplers
(unless post tire stroke)
Fasting lipids
Aspirin & dipyridamole
(Consider heparin for
evolving symptoms)
apriori contraindic
to thrombolysisa
arfarin with IN R 2.0 - 3.0
(unless contraindicated)
Stop anti-platelets
Small-vessel
cunai
urge-v s
(ipsilateral carotid artery stenosis > 70% )
° control
Lip'd control
Glycerine control if needed
Smoking cessation
Rehabilitation
Carotid endarterectomy
Alternative: angioplasty
with stenting
a Contraindications to t-PA: Prior intracranial hemorrhage; history of intracranial neoplasm, aneurysm or AVM; stroke or head trauma within
last 3 months; major surgery or biopsy of parenchymal organ within last 2 weeks; GI or genito-urinary bleeding within last 3 weeks; recent MI;
seizure at stroke onset; disorder of hemostasis; prothrombin time > 15 seconds; use of heparin in previous 48 hours with prolonged partial
thromboplastin time; use of low-molecular weight heparin during previous 48 hours; rapidly improving neurological deficit; mild, isolated
neurological deficit, e.g. ataxia, dysarthria, or sensory loss alone; systolic BP => 185 or diastolic BP > 110; platelet count < 100,0001mm'; blood
l ucose < 50 mgldL or > 400 mg(dL.
b Dosages. aspirin 75-300 mg po daily; dipyridamole 200 mg po twice daily or 100 mg po three times a day.
Oxygen
CBC, PT, PTT
Glu, lytes, BUN, Cr
BP to < 1851110
Rto contraindications to t-PA'
IV t-PA 0.9 rnvfkg
(10% as bolus, rest as
infusion, over I hour)
P)An lormanklementot stroke
DVT prophylaxis
	
pulmonary embolism risk.
All patients must receive subcutaneous heparin 5,000
BID for prevention of deep-vein thrombo=is and reduction of All patients must receive targeted secondar_,
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Secondary prevention
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Rehabilitation
Table. secondary prevention.
Therapy
	
Indication Strategy
Warfarin anticoagulation Presence of atrial fibrillation Maintain INR 2.0 - 3.0 (2.5 - 3.5 for patient
Presence of prosthetic heart valve with prosthetic valve)
Embolic stroke in post-Ml period
LV hypofunction (EF <35%)
Anti-platelet agents* All patients not requiring warfarin Aspirin 300 nig qd in combination with either: (i? dip)ridamole
100 mg tidi or (ii) clopidogrel 75 ing qd
Carotid endarterecton°iy Presence of internal carotid artery stenosis Referral to an experienced vascular surgeon with proven lox;
70-99% ipsilateral to brain infarction in a complication rate: carotid angiopiastq and scenting <,iso an
patient with some demonstrable ftmctional recovery option but safety and long-term efficac% unverified
* This recommendation is based on the author's best clinical judgment. Although data from randomized trials favors twice-daily Agarenox (aspirin 25 mg ,vith
extended-release dipyridamole 200 ing) as the most efficacious anti-platelet regimen in secondary stroke prevention. neither Agcrcnox nor extended-release
dipyridamole are available in Pakistan. The efficacy of combining regular dipyridamole with aspirin is unknown. The combination of aspirin and clopidogrel for
secondary stroke prevention is currently under investigation.
prevention to reduce the risk of stroke recurrence. Options
include anti-platelet therapy, oral anticoagulation with
warfarin 6 and carotid artery intervention.? indications for
their use are summarized in Table.
Risk Factor Management
All patients must undergo aggressive management of
all modifiable risk factors, including blood pressure control.
glycemie control in diabetics, cessation of cigarette smoking,
and reduction of serum LDL cholesterol to 100 mg/dL or less
with inhibitors of HMG-CoA reductase. A number of
medications are available for blood pressure reduction; some
evidence suggests that angiotension-converting enzyme
i nhibitors and diuretics may be particularly beneficial in
stroke patients.s The recommendation for serum LDL
cholesterol reduction is based on trails of HMG-CoA
reductase inhibitors ("statins") performed it, patients with
primary cardiac disease; results from trials in stroke patients
are currently awaited.
Rehabilitation requires a holistic approach that uses
multiple supportive strategies to help stroke patients achieve
maximum functional recovery. All patients should be offered
the benefits of rehabilitation therapy, including physical,
occupational and speech therapy, begun as early as feasible.
Training must be administered in multiple areas, including
gait, transfers and bed mobility, as well as speech/cognition
and manual dexterity (occupational therapy).
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Neuroprotective agents
Neuroprotective agents are drugs that inhibit the
biochemical consequences of stroke at the cellular level.
Although effective in animal models, so fat - no agent has
proven efficacious in human clinical trials; accordingly, the
use of neuroproteetive medication in ischemic stroke is not
recommended at present. 1 0 In Pakistan, a number of drugs are
marketed with claims of neuroprotection, including= a-ents
such as Hydergine (ergoioid inesYlate), Nootropil
(piracetam), and Encephabol (pyritinol). The use of these and
similar drugs is not supported by the available evidence.
Constraints
The above guidelines are based on evidence from
randomized trials or high quality observational studies. and
are internationally considered to be 'standard of care'. While
economic and logistical realities may make them unfeasible
for many practitioners in Pakistan, at a minimum the
investigational work-up of suspected stroke must include
cranial CT scanning. Clinical assessment alone cannot
distinguish intracerebral hemorrhage from ischemic stroke -
two coi-i ditions that demand a vastly different management
apprcac".
If the CT scan is normal or indicates infarction, anti-
platelet therapy can be safely begun. If carotid artery
intervention and the use of adjusted-dose warfarin with
frequent prothroinbin time monitoring are not feasible.
further work-up is unnecessary, and the anti.-platetet
treatment should be used indefinitely, along with risk factor
management as feasible.
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3.
Herpes simplex virus (HSV) infections are among
the most commonly encountered infections in human
beings. A pool of 30 million HSV infected patients exist in
USA. Two types of HSV infections have been identified
HSV-1, which usually causes orolabial disease, and HSV-2,
which is associated more frequently with -genital and
newborn infections. Usually, HSV causes mild and self-
limited disease of the mouth and lips or at genital sites.
However, on occasion, the disease can be life threatening.
Neonatal herpes infections occur in infants at a mean age of
14 days, but can happen up 10 1`011:- to six weeks after birth.
Clinical manifestations of neonatal infection can be
l ocalized to the slain, eye or mouth (SEM) or to the central
nervous system (CNS), such as encephalitis with or without
skin lesions. They can also present as disseminated sepsis.
Furthermore, in the immunocompromised host, severe
infection has been encountered and is a source of morbidity.
Even in the iminunoeompetent host, frequent recurrences,
particularly those of the genital tract, can be debilitating.
Because HSV does cause genital ulcerative disease, it is
associated with an increased risk of acquiring a human
i mmunodeficiency virus infection.
This article will summarize the natural history of
neonatal HSV encephalitis and will describe recent
developments in neonatal HSV disease management.
Epidemiology
Neonatal herpes simplex virus (HSV) infections may
be caused by either herpes sin,piex virus type-I (HSV-1) or
frel;pes simplex virus type-2 (HSV-2). In the United States,
HSV-2 is responsible for 75% of genital and neonatal
infections, while HSV-1 causes the rest. HSV-1 more
commonly affects the oropharynx, the eyes and the central
nervous system._.'- A pool of 30 million HSV infected
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patients exist it- USA. With 600,000 new cases occur each
year. 3 Sero prevalence has increased steadih from 16.49io
(1976-80) to 21.7% (1989-90). It is estimated that 20 to
30% of sexually active adults are seropositive for HSV-%.*
The majority of subjects with HSV infections .host likeiv
have unrecognized symptomatic infection.' - 6 Sixt\- to eivlltv .
percent of children with neonatal herpes are boll to :vOmel
with no known history of genital herpes.' Arnoas tllc:
women who deliver a HSV infected baby only 25° ,t, - 3,3°,:,
are symptorrlatic at delivery and or , !,, _;`/t - 19% have a:
history of HST,'°. In the largest epi;iernio!o lcal stad ,, o 70i?h?
pregnant women approximately':% acquired HSV tth?'illg
pregnancy 1 0 Postnatal acquisition o newborn d:Seasc is
rare but t? us occurred from :?asp:tat persol?l7el and ofleg .
caregivers with orolabial herpes.'" Among the women ;1vho
deliver a HSV infected baby only 25-33% are syrlptolnatic
at delivery and only 13-19% have a history of HS -V. i n the
l argest epidemiological Stttdy of 7,000 pregnant women
approximately ?% acquired HSV during pregnanc-,•.'
recent study has shown that about 3% Of i17Othefs _, o
susceptible to acquiring prltuary genltai HSV 4afCatiorr
during pregnancy._° Among tl- : s 3°/<,, i f the infection iv
acquired near the time of iabor, the risk of transn?
d=uring birth call reach 500o. A _)regnant ws =hart
	
,+ id? a
primary genital HSV-2 infection who has HSV-1 antibodies
i n her blood may have partial protection against HSV-2
vertical. transmission (risk of about 2i)`ioi,I yIi)i:hers
recurrent episodes of genital HSV have the lowest risk of
transmission between 0% to 5%. 1 2,13 The reported rate of
neonatal herpes infection varies in the United States
between 20 to 50 cases per 100,000 live births, while in the
United Kingdom and Australia it is about two or three cases
per 100,000 live births. Seroprevalence of HSV infection is
also high in Canadian surveys, 4 J 5
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